Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation

Phase 2 trial in patients with genital herpes shows correlation between viral load reduction and CD8 T cell activation, an important clinical surrogate Trial shows booster shot demonstrates sustainable, long-term effect June 23, 2014 Agenus Inc., an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, today announced promising Phase 2 results for …